Harrison, M. R., Jeraj, R., Hammers, H. J., Stein, M. N., Andrei, A., Perlman, S., … Liu, G. (2011). Phase I pharmacodynamic trial of sequential sunitinib (SU) with bevacizumab (bev) in patients with renal cell carcinoma (mRCC) and other advanced solid malignancies. Journal of Clinical Oncology, 29(15_suppl), e13503–e13503. https://doi.org/10.1200/jco.2011.29.15_suppl.e13503

Harrison, M. R., R. Jeraj, H. J. Hammers, M. N. Stein, A. Andrei, S. Perlman, J. Kolesar, et al. “Phase I pharmacodynamic trial of sequential sunitinib (SU) with bevacizumab (bev) in patients with renal cell carcinoma (mRCC) and other advanced solid malignancies.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): e13503–e13503. https://doi.org/10.1200/jco.2011.29.15_suppl.e13503.

Harrison MR, Jeraj R, Hammers HJ, Stein MN, Andrei A, Perlman S, et al. Phase I pharmacodynamic trial of sequential sunitinib (SU) with bevacizumab (bev) in patients with renal cell carcinoma (mRCC) and other advanced solid malignancies. Journal of Clinical Oncology. 2011 May 20;29(15_suppl):e13503–e13503.

Harrison, M. R., et al. “Phase I pharmacodynamic trial of sequential sunitinib (SU) with bevacizumab (bev) in patients with renal cell carcinoma (mRCC) and other advanced solid malignancies.” Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2011, pp. e13503–e13503. Crossref, doi:10.1200/jco.2011.29.15_suppl.e13503.

Harrison MR, Jeraj R, Hammers HJ, Stein MN, Andrei A, Perlman S, Kolesar J, Marnocha RM, Alberti DB, Wilding G, Liu G. Phase I pharmacodynamic trial of sequential sunitinib (SU) with bevacizumab (bev) in patients with renal cell carcinoma (mRCC) and other advanced solid malignancies. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011 May 20;29(15_suppl):e13503–e13503.